BiotechTube

Dexycu

Phase 3Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cataract

Conditions

Cataract

Trial Timeline

Sep 1, 2022 → Sep 1, 2023

NCT ID
NCT05550363

About Dexycu

Dexycu is a phase 3 stage product being developed by EyePoint Pharmaceuticals for Cataract. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05550363. Target conditions include Cataract.

What happened to similar drugs?

10 of 19 similar drugs in Cataract were approved

Approved (10) Terminated (2) Active (8)
🔄ISV-305Sun PharmaceuticalPhase 3
🔄ISV-305Sun PharmaceuticalPhase 3
🔄DE-108 + Levofloxacin 0.5%Santen PharmaceuticalPhase 3
✅Prednisolone acetateNovartisApproved
✅Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
✅Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
🔄Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1%Ocular TherapeutixPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05550350Phase 3Withdrawn
NCT05550363Phase 3Withdrawn

Competing Products

20 competing products in Cataract

See all competitors
ProductCompanyStageHype Score
ISV-305Sun PharmaceuticalPhase 3
40
ISV-303 + Bromday™Sun PharmaceuticalPhase 2
35
ISV-305Sun PharmaceuticalPhase 3
40
DE-108 + Levofloxacin 0.5%Santen PharmaceuticalPhase 3
40
Prednisolone acetateNovartisApproved
43
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
37
Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
37
Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1%Ocular TherapeutixPhase 3
34
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]Ocular TherapeutixPhase 2/3
24
Dexamethasone 0.4 MG [Dextenza]Ocular TherapeutixApproved
37
Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetateOcular TherapeutixApproved
37
Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic EmulsionOcular TherapeutixApproved
29
DexycuEyePoint PharmaceuticalsPhase 3
26
Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved
37
DEXYCU (dexamethasone intraocular suspension) 9%.EyePoint PharmaceuticalsPre-clinical
20
Dexamethasone + Prednisolone Acetate OphthalmicEyePoint PharmaceuticalsApproved
44
Bimatoprost Implant System (High Dose) + Bimatoprost Implant System (Low Dose) + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 1/2
30
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
41
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
41
OMS302 + OMS302-PE + VehicleOmeros CorporationPhase 1/2
26